Expert Perspectives: Tazemetostat in R/R FL
Panelists discuss how the updated NCCN Guidelines now recommend tazemetostat for the treatment of advanced epithelioid sarcoma, regardless of EZH2 mutation status, based on clinical trial data showing significant clinical benefits and improved progression-free survival in patients with both mutated and non-mutated disease.
Summary for Physicians:
NCCN Guidelines have recently been updated to recommend tazemetostat for the treatment of patients with epithelioid sarcoma, irrespective of EZH2 mutation status. Tazemetostat is an EZH2 inhibitor that works by targeting EZH2, an enzyme involved in the methylation of histone proteins, leading to the silencing of tumor suppressor genes. By inhibiting EZH2, tazemetostat helps to restore normal gene expression and suppresses tumor growth.
The guideline update is supported by data from clinical trials, specifically the EZH-202 study (NCT02601950), which demonstrated significant clinical benefit with tazemetostat in patients with advanced epithelioid sarcoma. Notably, the data showed durable responses and improved progression-free survival in patients with and without EZH2 mutations, supporting the inclusion of all patients, not just those with mutations, in treatment recommendations. This expansion is intended to provide broader access to this effective treatment for patients with this rare and aggressive sarcoma.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
